Significant Contract Modifications ($10M+) — August 12, 2026

Leidos' subsidiary QTC Medical Services won a $113.9M firm-fixed-price delivery order from the VA for medical disability exams, with $104.6M already outlaid, indicating strong execution and recurring revenue from a stable budget environment.

Jacobs Engineering won a $105.6M firm-fixed-price BPA call from DHS/CBP for construction management on 11 border patrol stations, with potential value of $162.3M including options, providing multi-year revenue visibility in a politically supported sector.

Palmetto GBA's 16-year, $212.5M CMS contract for Medicare administrative services ends in September 2024, with only $14.6M outlaid, creating a catalyst for either a re-compete or a sole-source follow-on that could signal incumbent advantage.

Roche's $183.8M BARDA contract for biodefense R&D is structured as cost-no-fee, meaning Roche earns no profit on the contract, limiting revenue upside despite the long-term (12-year) funding stream.

Jacobs Engineering's $105.6M firm-fixed-price contract for 11 border patrol station projects carries execution risk, as cost overruns on design-build projects could erode margins.

Palmetto GBA's $212.5M CMS contract has only $14.6M outlaid over 16 years, indicating potential concentration risk if the contract is not renewed or if funding is delayed, given the large gap between obligation and disbursement.

The Palmetto GBA contract's low outlay rate ($14.6M of $212.5M) raises questions about CMS funding execution or program prioritization, which could signal broader budget risks for HHS administrative contracts.

All four contracts were awarded under full and open competition with no set-asides, meaning incumbents like Palmetto GBA and Leidos face re-compete risks without guaranteed incumbent advantage.

Leidos (QTC Medical Services) could expand its VA medical disability examination market share by winning similar contracts in other regions, given its competitive win in the Midwest and the recurring nature of VA disability exams.

Jacobs Engineering's $105.6M DHS border security contract positions it for further infrastructure work as CBP continues to invest in border patrol stations, with options that could increase total value to $162.3M.

Palmetto GBA's expiring CMS contract in September 2024 presents an opportunity for either a sole-source follow-on (incumbent advantage) or a re-compete that could open the market to competitors, with a total potential value of $212.5M.

Roche's long-term BARDA contract (through 2028) for biodefense R&D could lead to follow-on contracts or product commercialization if R&D yields medical countermeasures, despite the cost-no-fee structure limiting near-term profit.

Three of four contracts (75% of total value) are in healthcare or social services, with HHS and VA awards totaling $510.2M, reflecting sustained federal investment in Medicare administration, biodefense R&D, and veteran benefits.

Jacobs Engineering's $105.6M DHS/CBP contract for border patrol station construction highlights sustained investment in border security, which straddles civilian and defense priorities and is politically supported across administrations.

All four contracts were awarded under full and open competition with no set-asides, indicating a competitive environment where incumbents like Palmetto GBA and Leidos must continuously defend their positions.

{"entity" => "Palmetto GBA LLC", "reason" => "Its $212.5M CMS contract expires in September 2024 with only $14.6M outlaid, creating uncertainty about renewal or re-compete.", "trigger" => "September 2024 contract expiration; CMS re-compete announcement"}

{"entity" => "Leidos Holdings Inc.", "reason" => "Its $113.9M VA contract has 92% outlay rate, indicating strong execution; future VA solicitations for medical exams in other regions could drive growth.", "trigger" => "VA future solicitations for medical disability exams in other regions"}

{"entity" => "Jacobs Engineering Group Inc.", "reason" => "Its $105.6M DHS contract has options that could increase value to $162.3M; execution on 11 design-build projects is critical.", "trigger" => "Option exercise announcements; quarterly project cost reports"}

{"entity" => "Hoffmann-La Roche Inc.", "reason" => "Its $183.8M BARDA contract is cost-no-fee, limiting profit; watch for option exercises or follow-on contracts that could improve terms.", "trigger" => "BARDA option exercise announcements; R&D pipeline milestones"}